Companies
RayzeBio
develops SSTR2-targeted radiopharmaceutical therapies for gastroenteropancreatic neuroendocrine tumors and operates a dedicated Indianapolis hub for end-to-end manufacturing and on-demand delivery of its clinical-stage RPT candidates.
- Country
- United States
targeted-alpha
us
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | Raised at least $418 million in equity capital by 2022 and planned a $173 million investment in 2026 to expand manufacturing operations in Indiana. | rayzebio.com · trial.medpath.com |
| Capacity | Designed to manufacture tens of thousands of doses annually when operating at full capacity. | rayzebio.com · trial.medpath.com · bms.com · ibj.com |
| Production site | Existing 77,000-square-foot facility in Indianapolis, Indiana; plans for a new 450,000-square-foot facility in Boone County, Indiana. | rayzebio.com · trial.medpath.com · ibj.com |
| Headcount | Approximately 100 employees as of July 2025, with plans to create up to 100 additional jobs by the end of 2029. | trial.medpath.com · ibj.com |
| Revenue | $380 million (2024), $250 million (2023), $90 million (2022), $120 million (2021), $65 million (2020). | privco.com · sec.gov |
Independent sources: bms.com · ibj.com · privco.com · sec.gov · trial.medpath.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Radiopharmaceuticals & theranostics | therapeutics-platforms | High | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.